Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: Improvement of their immune activity by expression of CD33-specific chimeric receptors

Haematologica

Volumn 95, Issue 12, 2010, Pages 2144-2152

  Marin, Virna ^a   Pizzitola, Irene ^a   Agostoni, Valentina ^a   Attianese, Greta Maria Paola Giordano ^a   Finney, Helene ^b   Lawson, Alastair ^b   Pule, Martin ^c   Rousseau, Raphael ^d   Biondi, Andrea ^a   Biagi, Ettore ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Acute myeloid leukemia; CD33; Cell therapy; Chimeric T cell receptor; Gene therapy

Indexed keywords

CD134 ANTIBODY; CD28 ANTIBODY; CD33 ANTIGEN; CD33 ZETA ANTIBODY; CD34 ANTIGEN; CELL RECEPTOR; CHIMERIC RECEPTOR; CHROMIUM 51; LYMPHOCYTE ANTIBODY; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL THERAPY; CELLULAR IMMUNITY; CHILD; CLONOGENESIS; COCULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DNA MODIFICATION; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL LINE; LYMPHOCYTE FUNCTION; MESENCHYME CELL; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ACUTE DISEASE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; CHILD; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HEK293 CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3; TIME FACTORS;

EID: 78649899281     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026310     Document Type: Article

References (41)

1. Linet MS, Devesa SS. Descriptive epidemiology of childhood leukaemia. Br J Cancer. 1991;63(3):424-9.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-907.
3. Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H, et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol. 2005;82 (5):449-55.
4. Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol. 2002;22(3):131-6.
5. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139-49.
6. Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006;38(9):621-7.
7. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92 (9):3318-27.
8. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002; 116(1):78-86.
9. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101 (2):640-8.
10. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006;34(9):1219-29.
11. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97(10):2923-31.
12. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001;7(10):532-42.
13. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer.;81(6):1009-16.
14. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, et al. Autologous cytokineinduced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004;10(8):1146-51.
15. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92 (7):952-9.
16. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, et al. Cytokineinduced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009;37 (5):616-28 e2.
17. Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol. 2007;35 (9):1388-97.
18. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215-23.
19. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933-41.
20. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens. 2009;74(4):277-89.
21. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108(12):3890-7.
22. Privitera E, Schiro R, Longoni D, Ronchi A, Rambaldi A, Bernasconi S, et al. Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. Blood. 1995; 86(1):323-8.
23. Cornish AL, Freeman S, Forbes G, Ni J, Zhang M, Cepeda M, et al. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood. 1998;92(6):2123-32.
24. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokineinduced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol. 2005;33(6):671-81.
25. Miller CL, Lai B. Human and mouse hematopoietic colony-forming cell assays. Methods Mol Biol. 2005;290:71-89.
26. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647-53.
27. MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006;12(7 Pt 2):2353s-8s.
28. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-83.
29. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104 (7):1995-9.
30. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 2008;34(1):49-60.
31. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295-302.
32. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoproteinmediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168-70.
33. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086-92.
34. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14(5):409-26.
35. Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007;15(7):1248-52.
36. Di Stasi A, Tey SK, Fujita Y, Cruz R, Martinez C, Kennedy-Nasser A, et al. CASPALLO: phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. Mol Ther. 2010;18:S110.
37. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009:675-81.
38. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2 (Suppl 1):S35-9.
39. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol. 2008;36(7): 755-68.
40. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma. 2009;50(8):1336-44.
41. Sutherlan MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, et al. Antileukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2009;1(5):481-90.